Lonza and Sanofi to build new multidisciplinary biomanufacturing facility in Switzerland

26 July 2017

Lonza Group, a life sciences-driven chemicals company, and French drugmaker Sanofi (Euronext: SAN) are to break ground on a new biopharmaceutical manufacturing facility at an existing site in Visp, Switzerland, to be designed around a flexible model of production.

First announced in February, the companies will invest 270 million euros ($285 million) in the jointly-owned facility, which is expected to be operational by 2020.

Lonza says it will offer: “an innovative new biological development and manufacturing concept, coupling flexibility in facility-build-out with fully tailored business models.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK